Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were initially developed for the treatment of type 2 diabetes mellitus and now have a key role in obesity management
These injections bypass the digestive system, allowing for better absorption of the vitamin directly into the bodys tissues
Increased risk of aspiration: Semaglutide increases the risk of aspiration during sedation and anesthesia
In contrast, AB106-156 monotherapy maintained a 15% weight reduction, preserving most of its maximal weight loss (-18%), showed minimal weight rebound (+2.7%)
Weight loss programs that include semaglutide give them a realistic path to achieving and maintaining their goals
Keeping blood sugar stable, staying hydrated, improving sleep, managing stress, and addressing digestive issues can all help improve mood